0641U prior authorization | Blue Cross Blue Shield Oklahoma

0641U, Oncology minimal residual disease tumor DNA analysis using next-generation sequencing of FFPE tissue and blood sample, initial test, is on the Blue Cross Blue Shield Oklahoma commercial prior authorization list. Not a coverage or referral decision.

Code: 0641U
Description: Oncology minimal residual disease tumor DNA analysis using next-generation sequencing of FFPE tissue and blood sample, initial test
Source: 2026 Commercial Outpatient Medical Surgical ASO Prior Authorization Codes, Pg 226 Original policy

Blue Cross Blue Shield Oklahoma prior authorization

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.